Repligen Corp. Stock
Repligen Corp. Stock
The price for the Repligen Corp. stock decreased slightly today. Compared to yesterday there is a change of -€1.250 (-0.880%).
With 18 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 158 € there is a slightly positive potential of 11.94% for Repligen Corp. compared to the current price of 141.15 €.
So far the community has only identified positive things for Repligen Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Repligen Corp. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Repligen Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Repligen Corp. | -0.880% | -4.075% | 11.207% | 0.743% | 1.751% | -20.349% | -8.247% |
| Opko Health Inc. | 4.010% | 2.292% | -6.313% | -22.272% | -20.302% | -18.675% | -71.164% |
| Amicus Therapeutics Inc. | 0.610% | -3.509% | 5.096% | -10.326% | -9.836% | -28.123% | -57.254% |
| Hutchison China Meditech Ltd | 0.880% | -0.862% | -9.449% | -26.282% | -10.853% | -8.730% | -50.644% |
Comments
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was given a new $150.00 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock.
Show more
Ratings data for RGEN provided by MarketBeat